Anti-Meth Draft Places PSE Behind Counter, Lacks Schedule V Language
This article was originally published in The Tan Sheet
Executive Summary
Current draft report language in the Patriot Act places all pseudoephedrine products behind the counter but does not contain a Schedule V provision, according to the Consumer Healthcare Products Association
You may also be interested in...
CHPA Year In Review: Legislative Accomplishments, OTC Product Awareness And Goals For 2006
The Consumer Healthcare Products Association speaks to "The Tan Sheet" about the group's accomplishments in 2005 and plans for 2006. The 125 year-old trade association represents the interests of the consumer healthcare and over-the-counter drugs industries. Find below excerpts from an interview with CHPA President Linda Suydam and Vice President - Government Relations Kevin Kraushaar
Patriot Act and PSE
Provisions requiring behind-the-counter placement of products containing pseudoephedrine have been added to the final version of the conference report for the Patriot Act reauthorization package. The report was filed Dec. 8 and will be considered by the House and Senate during the week of Dec. 12, House Judiciary Committee Chairman James Sensenbrenner (R-Wis.), announces. The provision for BTC sale was first added to the draft version of the conference report in November (1"The Tan Sheet" Nov. 28, 2005, p. 3). Also added at that time were essentially all elements of the Talent/Feinstein Combat Meth Act (S 103), except for the provision requiring Schedule V status for pseudoephedrine. The conference report's final version contains a new pseudoephedrine sales limit of 9 g/30 days...
Pseudoephedrine Sales Limit Provisions Attached To Patriot Act
The Talent/Feinstein Combat Meth Act (S 103) that would place behind-the-counter restrictions on pseudoephedrine was added to the Patriot Act reauthorization package in conference discussions Nov. 17